samedan logo
 
 
 
spacer
home > pmps > summer 2020 > enhancing parenteral packaging security
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Enhancing Parenteral Packaging Security

Thanks to the EU Falsified Medicines Directive that has been in effect since February 2019, tampering with secondary medicine packaging has become more difficult. But, what about primary containers such as vials and syringes or autoinjectors? They continue to be exposed to the risk of tampering although first-opening indication for patient protection would be particularly important in these cases: a security gap that specialty labeling solutions and concepts can close. Fake medicines inflict considerable damage on the pharmaceutical industry, but above all, they pose a massive risk to patient safety. About 1 million people per year die due to counterfeit medicines, according to WHO. Operation ‘MISMED 2’ conducted in 2018 by Europol, the European Agency for Law Enforcement Cooperation, once again revealed the magnitude of this issue: during the seven-month-long investigations, 13 million illegal medicines worth €165 million were confiscated – including opiates, energy enhancers, drugs for cancer, and coronary disease therapies. In total, 16 European countries were involved in the operation that broke up a total of 24 groups of organised crime. About 50% of the seized substances were fake medicines – posing a severe health risk, particularly to patients suffering from serious illnesses. Recently, in March 2020, Interpol’s Operation ‘Pangea’, targeting online sale of illicit medicines and medical devices, seized 4.4 million units of counterfeit and illegal pharmaceuticals worldwide worth $14 milllion. In this context, it also became obvious that there is a rise in fake medical products related to COVID-19.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Liliane Pfeiffer is Product Manager Tamper-Evident Solutions at Schreiner MediPharm, a business unit of Schreiner Group based in Oberschleissheim near Munich, Germany. Schreiner MediPharm develops and produces innovative, multi-functional specialty labels with value-added benefits for the healthcare industry. Liliane is in charge of managing the product portfolio, which covers tamper-evident solutions tailored to customers’ specific requirements for effective anti-tampering and anti-counterfeiting protection. She joined Schreiner MediPharm in 2017, assuming a position in the Sales Department, and since 2019, she has been working in Business Development. Liliane obtained her PhD (molecular epidemiologic research) in Nutrition and Biomedicine from the Technical University of Munich, Germany.
spacer
Liliane Pfeiffer
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

First Patients Treated in First-in-Human Trial for Innovative Liver and Pancreas Sealant Patch

Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, today announced treatment of the first patients in its first-in-human study for ACTISEAL, its Liver and Pancreas Sealant Patch.
More info >>

White Papers

Igb Tamper Evident Folding Box

IGB

The easiest, safest and less expensive solution in compliance with what requires Dir. 62/2011/EU, FDA and TGA.
More info >>

 
Industry Events

CPhI Festival of Pharma

5-16 October 2020, Virtual

A virtual gathering for the pharmaceutical industry, the CPhI Festival of Pharma has been created to fill the gap left by in-person events at a time when travel and gatherings are off the cards.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement